A phase I trial of BNC105P and ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia
Open Access
Abstract
No abstract availableThis publication has 14 references indexed in Scilit:
- Rapid induction of apoptosis in chronic lymphocytic leukemia cells by the microtubule disrupting agent BNC105Cancer Biology & Therapy, 2016
- Vincristine activates c‐Jun N‐terminal kinase in chronic lymphocytic leukaemia in vivoBritish Journal of Clinical Pharmacology, 2015
- Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapyBlood, 2014
- Toward a cure for chronic lymphocytic leukemia: an attack on multiple frontsExpert Review of Anticancer Therapy, 2013
- Vinblastine Rapidly Induces NOXA and Acutely Sensitizes Primary Chronic Lymphocytic Leukemia Cells to ABT-737Molecular Cancer Therapeutics, 2013
- Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic LeukemiaNew England Journal of Medicine, 2013
- Clinical, Pharmacodynamic, and Pharmacokinetic Evaluation of BNC105P: A Phase I Trial of a Novel Vascular Disrupting Agent and Inhibitor of Cancer Cell ProliferationClinical Cancer Research, 2011
- Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemiaBlood, 2008
- Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelinesBlood, 2008
- Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocytic leukemiaLeukemia & Lymphoma, 2008